Germany’s Hexal AG is taking the European Medicines Agency to court over its refusal to accept a marketing authorization application (MAA) for its generic version of Sanofi’s multiple sclerosis (MS) drug Aubagio (teriflunomide).
According to Hexal (part of Sandoz), the EMA was wrong to decide in 2013 that teriflunomide was a new active...